Leland Gerschel

Leland Gerschel asked about Compugen's plans for presenting data at various oncology meetings (ESMO, SITC) through 2026, specifically regarding COM-701 updates.

Answer

Eran Ophir (President and CEO) stated that for Gilead's GS-0321, data could be presented at medical conferences this year, and AstraZeneca might report rilvegostomig clinical readouts at scientific conferences, though no specific dates were disclosed. The MAIA-ovarian study readout is expected next year (Q1 2027).

Leland Gerschel asked about Compugen's plans for presenting data at oncology meetings like ESMO and SITC throughout 2026, ahead of the Q1 2027 COM-701 update.

Answer

Eran Ophir (President and CEO) stated that for Gilead's GS-0321, data could be presented at a medical conference this year, pending alignment with Gilead. He also mentioned that AstraZeneca might report clinical readouts for rilvegostomig at scientific conferences this year, but no specific timing was disclosed.